Published in Pharma Investments, Ventures and Law Weekly, July 17th, 2005
The action related to the agreement for the exercise of share options granted to Geaney during his period as an employee of the company.
The settlement, with no admission of liability on the part of the company, was for a sum of EUR 3.5 million plus an agreed sum of costs.
Elan Corp., plc, is a neuroscience-based biotechnology company. Elan shares trade on the New York, London, and Dublin stock exchanges.
This article was prepared by Pharma Investments, Ventures & Law Weekly editors from staff and...
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Pharma Investments, Ventures and Law Weekly
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.